BioMarin Pharmaceutical (BMRN) Expected to Announce Quarterly Earnings on Wednesday

BioMarin Pharmaceutical (NASDAQ:BMRN) is anticipated to post its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect BioMarin Pharmaceutical to post earnings of $0.80 per share and revenue of $834.3160 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 18, 2026 at 4:30 PM ET.

BioMarin Pharmaceutical Stock Performance

NASDAQ BMRN opened at $59.66 on Wednesday. The company has a 50-day simple moving average of $56.88 and a two-hundred day simple moving average of $55.91. BioMarin Pharmaceutical has a 12-month low of $50.76 and a 12-month high of $73.51. The firm has a market cap of $11.46 billion, a price-to-earnings ratio of 22.43, a PEG ratio of 0.63 and a beta of 0.26. The company has a quick ratio of 3.10, a current ratio of 4.83 and a debt-to-equity ratio of 0.10.

Institutional Trading of BioMarin Pharmaceutical

A number of institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd purchased a new position in shares of BioMarin Pharmaceutical during the third quarter valued at approximately $40,000. Parallel Advisors LLC lifted its holdings in shares of BioMarin Pharmaceutical by 62.2% during the 3rd quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 295 shares during the period. Voleon Capital Management LP purchased a new position in shares of BioMarin Pharmaceutical in the 2nd quarter worth $226,000. Sivia Capital Partners LLC grew its holdings in shares of BioMarin Pharmaceutical by 33.0% in the second quarter. Sivia Capital Partners LLC now owns 4,439 shares of the biotechnology company’s stock worth $244,000 after acquiring an additional 1,102 shares during the period. Finally, NewEdge Advisors LLC lifted its holdings in BioMarin Pharmaceutical by 11.5% in the first quarter. NewEdge Advisors LLC now owns 3,769 shares of the biotechnology company’s stock valued at $266,000 after acquiring an additional 388 shares during the period. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on BMRN shares. Wells Fargo & Company reduced their target price on BioMarin Pharmaceutical from $90.00 to $70.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 28th. Canaccord Genuity Group raised shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and boosted their price objective for the company from $84.00 to $98.00 in a research report on Tuesday, January 20th. Wedbush reaffirmed an “outperform” rating and issued a $94.00 target price on shares of BioMarin Pharmaceutical in a research report on Tuesday, October 28th. Piper Sandler cut their target price on shares of BioMarin Pharmaceutical from $122.00 to $84.00 and set an “overweight” rating on the stock in a research note on Friday, February 6th. Finally, Truist Financial increased their price target on shares of BioMarin Pharmaceutical from $80.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, December 23rd. Seventeen research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, BioMarin Pharmaceutical presently has an average rating of “Moderate Buy” and an average price target of $88.29.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.